Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：26
|
作者：
Diedhiou, Demba [1 ,2 ]
Cuny, Thomas [1 ]
Sarr, Anna [2 ]
Diop, Said Norou [2 ]
Klein, Marc [1 ]
Weryha, Georges [1 ]
机构：
[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France
[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal
来源：
ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期
关键词：
Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;
D O I：
10.1016/j.ando.2015.10.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：650 / 657
页数：8
相关论文
共 50 条
  • [31] Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis A Meta-Analysis
    Gu, Hai-Feng
    Gu, Ling-Jia
    Wu, Yue
    Zhao, Xiao-Hong
    Zhang, Qing
    Xu, Zhe-Rong
    Yang, Yun-Mei
    MEDICINE, 2015, 94 (44) : e1674
  • [32] LONG-TERM EFFICACY AND SAFETY OF DENOSUMAB IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Papapoulos, S. E.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 411 - 412
  • [33] Osteoporosis and CKD-MBD in hemodialysed patients: efficacy and safety of denosumab
    Bracaccia, Maria Elena
    Moioli, Alessandra
    Fofi, Claudia
    Mene, Paolo
    Festuccia, Francescaromana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2543 - I2543
  • [34] SUSTAINABILITY OF ANTI-FRACTURE EFFICACY AND SAFETY OF DENOSUMAB IN POSTMENOPAUSAL OSTEOPOROSIS
    Kendler, D.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S653 - S654
  • [35] Denosumab for the treatment of osteoporosis
    Zaheer, Sarah
    LeBoff, Meryl
    Lewiecki, Michael
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (03) : 461 - 470
  • [36] Treatment of osteoporosis with denosumab
    Lewiecki, E. Michael
    MATURITAS, 2010, 66 (02) : 182 - 186
  • [37] Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
    Wan, Y.
    Zeng, F.
    Tan, H.
    Lu, Y.
    Zhang, Y.
    Zhao, L.
    You, R.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (05) : 979 - 1015
  • [38] Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
    Y. Wan
    F. Zeng
    H. Tan
    Y. Lu
    Y. Zhang
    L. Zhao
    R. You
    Osteoporosis International, 2022, 33 : 979 - 1015
  • [39] Efficacy and Safety of Anti-Sclerostin Antibodies in the Treatment of Osteoporosis: A Meta-Analysis and Systematic Review
    Poutoglidou, Frideriki
    Samoladas, Efthimios
    Raikos, Nikolaos
    Kouvelas, Dimitrios
    JOURNAL OF CLINICAL DENSITOMETRY, 2022, 25 (03) : 401 - 415
  • [40] Denosumab for the treatment of osteoporosis
    Iqbal J.
    Sun L.
    Zaidi M.
    Current Osteoporosis Reports, 2010, 8 (4) : 163 - 167
12345